Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-04-03
2007-04-03
Prouty, Rebecca E. (Department: 1652)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023200, C536S023500, C536S024300, C536S024310, C536S024330, C536S025320, C435S194000
Reexamination Certificate
active
10325810
ABSTRACT:
The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
REFERENCES:
patent: 3817837 (1974-06-01), Rubenstein et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3939350 (1976-02-01), Kronick et al.
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4275149 (1981-06-01), Litman et al.
patent: 4277437 (1981-07-01), Maggio
patent: 4366241 (1982-12-01), Tom et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5416017 (1995-05-01), Burton et al.
patent: 5489508 (1996-02-01), West et al.
patent: 5583016 (1996-12-01), Villeponteau et al.
patent: 5631236 (1997-05-01), Woo et al.
patent: 5728379 (1998-03-01), Martuza et al.
patent: 5747317 (1998-05-01), Cao
patent: 5770422 (1998-06-01), Collins
patent: 5907083 (1999-05-01), Robert et al.
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 6054575 (2000-04-01), Villeponteau et al.
patent: 6083717 (2000-07-01), Madzak et al.
patent: 6093809 (2000-07-01), Cech et al.
patent: 6175060 (2001-01-01), Lefebvre et al.
patent: 6228643 (2001-05-01), Greenland et al.
patent: 6261556 (2001-07-01), Weinrich et al.
patent: 6261836 (2001-07-01), Cech et al.
patent: 6271437 (2001-08-01), Jessen et al.
patent: 6274790 (2001-08-01), Kunst et al.
patent: 6281409 (2001-08-01), Woodhead et al.
patent: 6300095 (2001-10-01), Barredo Fuente et al.
patent: 6306656 (2001-10-01), Liu et al.
patent: 6331527 (2001-12-01), Parmacek et al.
patent: 6686159 (2004-02-01), Andrews et al.
patent: 6916642 (2005-07-01), Kilian et al.
patent: 2003/0050264 (2003-03-01), Andrews et al.
patent: 2003/0096732 (2003-05-01), Andrews et al.
patent: 2003/0104420 (2003-06-01), Andrews
patent: 2003/0113760 (2003-06-01), Andrews et al.
patent: 2003/0171326 (2003-09-01), Andrews et al.
patent: 2003/0211965 (2003-11-01), Andrews et al.
patent: 2317891 (1998-04-01), None
patent: 09154575 (1997-06-01), None
patent: WO 84/03564 (1984-09-01), None
patent: WO 95/13382 (1995-05-01), None
patent: WO 96/01835 (1996-01-01), None
patent: WO 96/12811 (1996-05-01), None
patent: WO 96/19580 (1996-06-01), None
patent: WO 96/40868 (1996-12-01), None
patent: WO 98/01542 (1998-01-01), None
patent: WO 98/01543 (1998-01-01), None
patent: WO 98/07838 (1998-02-01), None
patent: WO 98/08938 (1998-03-01), None
patent: WO 98/14592 (1998-04-01), None
patent: WO 98/14593 (1998-04-01), None
patent: WO 98/14593 (1998-05-01), None
patent: WO 98/21343 (1998-05-01), None
patent: WO 98/37181 (1998-08-01), None
patent: WO 98/45450 (1998-10-01), None
patent: WO 98/59040 (1998-12-01), None
patent: WO 99/01560 (1999-01-01), None
patent: WO 99/33998 (1999-07-01), None
patent: WO 99/38964 (1999-08-01), None
patent: WO 00/46355 (2000-08-01), None
patent: WO 02/16657 (2002-02-01), None
patent: WO 02/16658 (2002-02-01), None
patent: WO 02/070668 (2002-09-01), None
patent: WO 02/072787 (2002-09-01), None
patent: WO 02/090570 (2002-11-01), None
patent: WO 02/090571 (2002-11-01), None
patent: WO 02/101010 (2002-12-01), None
patent: WO 03/000916 (2003-01-01), None
patent: WO 03/016474 (2003-02-01), None
Genbank AA281296, EST Apr. 2, 1997.
Berenstein, M., et al., “Different efficacy ofin vivoherpes simplex virus thymidine kinase gene transduction and ganciclovir treatment on the inhibition of tumor growth of murine and human melanoma cells and rat glioblastoma cells”,Cancer Gene Therapy, 6(4):358-366 (1999).
Bi, W., et al., “An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice”,Cancer Gene Therapy, 4(4):246-252 (1997).
Brand, K., et al., “Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach”,Gene Therapy, 5:1363-1371 (1998).
Devereux, T.R., et al., “DNA Methylation Analysis of the Promoter Region of the Human Telomerase Reverse Transcriptase (hTERT) Gene”,Cancer Res., 59:6087-6090 (Dec. 15, 1999).
Elshami, A.A., et al., “The effect of promoter strength in adenoviral vectors containing herpes simplex virus thymidine kinase on cancer gene therapyin vitroandin vivo”, Cancer Gene Therapy, 4(4):231-221 (1997).
Horikawa, I., et al., “Cloning and Characterization of the Promoter Region ofHuman Telomerase Reverse Transcriptase Gene”, Cancer Res., 59:826-830 (Feb. 15, 1999).
Klatzmann, D., et al., “A Phase I/II Dose-Escalation Study of Herpes Simplex Virus Type I Thymidine Kinase “Suicide” Gene Therapy for Metastatic Melanoma”,Human Gene Therapy, 9:2585-2594 (Nov. 20, 1998).
Klatzmann, D., et al., “A Phase I/II Study of Herpes Simplex Virus Type I Thymidine Kinase “Suicide” Gene Therapy for Recurrent Glioblastoma”,Human Gene Therapy, 9:2595-2604 (Nov. 20, 1998).
Li, P.-X., et al., “Differential chemosensitivity of breast cancer cells to ganciclovir treatment following adenovirus-mediated herpes simplex virus thymidine kinase gene transfer”,Cancer Gene Therapy, 6(2):179-190 (1999).
Princen, F., et al., “Repeated cycles of retrovirus-mediated HSVtk gene transfer plus ganciclovir increase survival of rats with peritoneal carcinomatosis”,Gene Therapy, 5:1054-1060 (1998).
Robertson, M.W., III, et al., “Use of a tissue-specific promoter for targeted expression of the herpes simplex virus thymidine kinase gene in cervical carcinoma cells”,Cancer Gene Therapy, 5(5):331-336 (1998).
Shand, N., et al., “A Phase 1-2 Clinical Trial of Gene Therapy for Recurrent Giloblastoma Multiforme by Tumor Transduction with the Herpes Simplex Thymidine Kinase Gene Followed by Ganciclovir”,Human Gene Therapy, 10:2325-2335 (Sep. 20, 1999).
Siders, W.M., et al., “Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus”,Cancer Gene Therapy, 5(5):281-291 (1998).
Smiley, W.R., et al., “Establishment of Parameters for Optimal Transduction Efficiency and Antitumor Effects with Purified High-Titer HSV-TK Retroviral Vector in Established Solid Tumors”,Human Gene Therapy, 8:965-977 (May 20, 1997).
Sterman, D.H., et al., “Adenovirus-Mediated Herpes Simplex Virus Thymidine Kinase/Ganciclovir Gene Therapy in Patients with Localized Malignancy: Results of a Phase I Clinical Trial in Malignant Mesothelioma”,Human Gene Therapy, 9:1083-1092 (May 1, 1998).
Su, H., et al., “Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice”,Proc. Natl. Acad. Sci. USA, 94 :13891-13896 (Dec. 1997).
Takakura, M., et al., “Cloning of Human Telomerase Catalytic Subunit (hTERT) Gene Promoter and Identification of Proximal Core Promoter Sequences Essential for Transcriptional Activation in Immortalized and Cancer Cells”,Cancer Res., 59:551-557 (Feb. 1, 1999).
Wick, M., et al., “Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT)”,Gene, 232:97-106 (1999).
Wildner, O., et al., “Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer”,Gene Therapy, 6:57-62 (1999).
Wildner, O., et al., “Therapy of Colon Cancer with Oncolytic Adenovirus is Enhanced by the Addition of Herpes Simplex Virus-thymidine kinase”,Cancer Research, 59:410/413 (1999).
Wu, K.-J., et al., “Direct activation ofTERTtranscription by c-MYC”,Nature Genetics, 21:220-224 (Feb. 1999).
Y
Andrews William H.
Morin Gregg B.
Earp David J.
Geron Corporation
Prouty Rebecca E.
Schiff J. Michael
Walicka Malgorzata
LandOfFree
Regulatory segments of the human gene for telomerase reverse... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Regulatory segments of the human gene for telomerase reverse..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regulatory segments of the human gene for telomerase reverse... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3763240